

Contents

Preface xiii

Glossary xv

1. Introduction to Biopharmaceutics and Pharmacokinetics 1

Drug Product Performance	1
Biopharmaceutics	1
Pharmacokinetics	3
Clinical Pharmacokinetics	4
Practical Focus	4
Pharmacodynamics	5
Drug Exposure and Drug Response	5
Toxicokinetics and Clinical Toxicology	5
Measurement of Drug Concentrations	6
Basic Pharmacokinetics and Pharmacokinetic Models	10
Chapter Summary	15
Learning Questions	17
References	17
Bibliography	18

2. Mathematical Fundamentals in Pharmacokinetics 19

Math Self-Exam	19
Estimation and the Use of Calculators and Computers	20
Practice Problems	22
Calculus	24
Graphs	26
Units in Pharmacokinetics	31
Measurement and Use of Significant Figures	32
Units for Expressing Blood Concentrations	33
Statistics	33
Practical Focus	34
Rates and Orders of Reactions	35
Chapter Summary	40
Learning Questions	40
References	42
Bibliography	42

3. One-Compartment Open Model: Intravenous Bolus Administration 43

Elimination Rate Constant	44
Apparent Volume of Distribution	45
Clearance	48
Practical Focus	50
Clinical Application	53
Calculation of k from Urinary Excretion Data	53
Practice Problem	54
Clinical Application	56
Chapter Summary	57
Learning Questions	57
Reference	59
Bibliography	59

4. Multicompartment Models: Intravenous Bolus Administration 61

Two-Compartment Open Model	63
Clinical Application	68
Practice Problem	68
Practical Focus	69
Three-Compartment Open Model	77
Determination of Compartment Models	79
Practical Application	84
Chapter Summary	86
Learning Questions	87
References	88
Bibliography	89

5. Intravenous Infusion 91

One-Compartment Model Drugs	91
Infusion Method for Calculating Patient Elimination Half-Life	95

- Loading Dose Plus IV Infusion—One-Compartment Model 96
 Practice Problems 98
 Estimation of Drug Clearance and V_D from Infusion Data 100
 Intravenous Infusion of Two-Compartment Model Drugs 100
 Practical Focus 102
 Chapter Summary 104
 Learning Questions 104
 Reference 106
 Bibliography 106
- 6. Drug Elimination and Clearance 107**
- Drug Elimination 107
 The Kidney 108
 Renal Drug Excretion 111
 Clinical Application 114
 Practice Problems 114
 Drug Clearance 114
 Clearance Models 116
 Renal Clearance 118
 Determination of Renal Clearance 121
 Relationship of Clearance to Elimination Half-Life and Volume of Distribution 125
 Chapter Summary 127
 Learning Questions 127
 References 129
 Bibliography 129
- 7. Pharmacokinetics of Oral Absorption 131**
- Pharmacokinetics of Drug Absorption 131
 Significance of Absorption Rate Constants 133
 Zero-Order Absorption Model 133
 Clinical Application—Transdermal Drug Delivery 134
 First-Order Absorption Model 134
 Practice Problem 142
 Chapter Summary 149
 Learning Questions 149
 References 150
 Bibliography 151
- 8. Multiple-Dosage Regimens 153**
- Drug Accumulation 153
 Clinical Example 157
 Repetitive Intravenous Injections 158
 Intermittent Intravenous Infusion 163
 Estimation of k and V_D of Aminoglycosides in Clinical Situations 165
 Multiple-Oral-Dose Regimen 166
 Loading Dose 168
- Dosage Regimen Schedules 169
 Practice Problems 171
 Chapter Summary 173
 Learning Questions 174
 References 175
 Bibliography 175
- 9. Nonlinear Pharmacokinetics 177**
- Saturable Enzymatic Elimination Processes 179
 Practice Problem 180
 Drug Elimination by Capacity-Limited Pharmacokinetics: One-Compartment Model, IV Bolus Injection 181
 Clinical Focus 191
 Drugs Distributed as One-Compartment Model and Eliminated by Nonlinear Pharmacokinetics 191
 Chronopharmacokinetics and Time-Dependent Pharmacokinetics 193
 Bioavailability of Drugs that Follow Nonlinear Pharmacokinetics 196
 Nonlinear Pharmacokinetics Due to Drug-Protein Binding 196
 Potential Reasons for Unsuspected Nonlinearity 200
 Chapter Summary 200
 Learning Questions 200
 References 202
 Bibliography 203
- 10. Physiologic Drug Distribution and Protein Binding 205**
- Physiologic Factors of Distribution 205
 Clinical Focus 213
 Apparent Volume Distribution 213
 Practice Problem 216
 Protein Binding of Drugs 219
 Clinical Examples 221
 Effect of Protein Binding on the Apparent Volume of Distribution 222
 Relationship of Plasma Drug-Protein Binding to Distribution and Elimination 227
 Determinants of Protein Binding 231
 Kinetics of Protein Binding 232
 Practical Focus 233
 Determination of Binding Constants and Binding Sites by Graphic Methods 233
 Clinical Significance of Drug-Protein Binding 236
 Modeling Drug Distribution 247
 Chapter Summary 248
 Learning Questions 249
 References 250
 Bibliography 251

11. Drug Elimination and Hepatic Clearance 253

- Route of Drug Administration and Extrahepatic Drug Metabolism 253
- Practical Focus 255
- Hepatic Clearance 255
- Enzyme Kinetics 257
- Clinical Example 261
- Practice Problem 263
- Anatomy and Physiology of the Liver 265
- Hepatic Enzymes Involved in the Biotransformation of Drugs 267
- Drug Biotransformation Reactions 269
- Pathways of Drug Biotransformation 270
- First-Pass Effects 282
- Hepatic Clearance of a Protein-Bound Drug: Restrictive and Nonrestrictive Clearance from Binding 287
- Effect of Changing Intrinsic Clearance and/or Blood Flow on Hepatic Extraction and Elimination Half-Life after IV and Oral Dosing 288
- Biliary Excretion of Drugs 289
- Role of Transporters in Hepatic Clearance and Bioavailability 292
- Chapter Summary 293
- Learning Questions 294
- References 296
- Bibliography 298

12. Pharmacogenetics 301

- Polymorphism 303
- Pharmacogenomics 306
- Adverse Drug Reactions Attributed to Genetic Differences 308
- Genetic Polymorphism in Drug Metabolism: Cytochrome P-450 Isozymes 310
- Genetic Polymorphism in Drug Transport: MDR1 (P-Glycoprotein) and Multidrug Resistance 311
- Genetic Polymorphism in Drug Targets 312
- Relationship of Pharmacokinetics/Pharmacodynamics and Pharmacogenetics/Pharmacogenomics 313
- Clinical Example 315
- Summary 316
- Glossary 316
- Abbreviations 317
- References 317
- Bibliography 318

13. Physiologic Factors Related to Drug Absorption 321

- Drug Absorption and Design of a Drug Product 321
- Route of Drug Administration 321
- Nature of Cell Membranes 324
- Passage of Drugs Across Cell Membranes 326
- Oral Drug Absorption During Drug Product Development 333
- Drug Interactions in the Gastrointestinal Tract 334
- Oral Drug Absorption 336
- Methods for Studying Factors that Affect Drug Absorption 348
- Clinical Examples 351
- Effect of Disease States on Drug Absorption 351
- Miscellaneous Routes of Drug Administration 353
- Chapter Summary 355
- Learning Questions 356
- References 357
- Bibliography 359

14. Biopharmaceutic Considerations in Drug Product Design and *In Vitro* Drug Product Performance 361

- Biopharmaceutic Factors Affecting Drug Bioavailability 361
- Rate-Limiting Steps in Drug Absorption 363
- Physicochemical Nature of the Drug 366
- Formulation Factors Affecting Drug Product Performance 368
- Drug Product Performance, *In Vitro*: Dissolution and Drug Release Testing 370
- Compendial Methods of Dissolution 374
- Alternative Methods of Dissolution Testing 376
- Meeting Dissolution Requirements 378
- Problems of Variable Control in Dissolution Testing 379
- Performance of Drug Products: *In Vitro*–*In Vivo* Correlation 380
- Dissolution Profile Comparisons 386
- Drug Product Stability 386
- Considerations in the Design of a Drug Product 387
- Drug Product Considerations 389
- Clinical Example 394
- Chapter Summary 398
- Learning Questions 399
- References 399
- Bibliography 401

- 15. Drug Product Performance, *In Vivo*: Bioavailability and Bioequivalence 403**
- Drug Product Performance 403
 - Purpose of Bioavailability Studies 405
 - Relative and Absolute Availability 406
 - Practice Problem 407
 - Methods for Assessing Bioavailability 407
 - Bioequivalence Studies 413
 - Design and Evaluation of Bioequivalence Studies 414
 - Study Designs 417
 - Crossover Study Designs 418
 - Clinical Example 422
 - Evaluation of the Data 423
 - Bioequivalence Example 424
 - Study Submission and Drug Review Process 427
 - The Biopharmaceutics Classification System 431
 - Generic Biologics (Biosimilar Drug Products) 433
 - Clinical Significance of Bioequivalence Studies 435
 - Special Concerns in Bioavailability and Bioequivalence Studies 436
 - Generic Substitution 437
 - Glossary 440
 - Chapter Summary 443
 - Learning Questions 443
 - References 448
 - Bibliography 449
- 16. Impact of Drug Product Quality and Biopharmaceutics on Clinical Efficacy 451**
- Risks From Medicines 451
 - Drug Product Quality and Drug Product Performance 452
 - Pharmaceutical Development 453
 - Excipient Affect on Drug Product Performance 455
 - Practical Focus 456
 - Quality Control and Quality Assurance 457
 - Risk Management 459
 - Scale-Up and Postapproval Changes (SUPAC) 461
 - Product Quality Problems 464
 - Postmarketing Surveillance 465
 - Glossary 465
 - Chapter Summary 466
 - Learning Questions 466
 - References 466
- 17. Modified-Release Drug Products 469**
- Conventional (Immediate-Release) and Modified-Release Drug Products 469
 - Biopharmaceutic Factors 473
 - Dosage form Selection 475
 - Advantages and Disadvantages of Extended-Release Products 475
 - Kinetics of Extended-Release Dosage Forms 476
 - Pharmacokinetic Simulation of Extended-Release Products 478
 - Clinical Examples 480
 - Types of Extended-Release Products 480
 - Considerations in the Evaluation of Modified-Release Products 495
 - Evaluation of Modified-Release Products 497
 - Evaluation of *In Vivo* Bioavailability Data 499
 - Chapter Summary 501
 - Learning Questions 501
 - References 502
 - Bibliography 503
- 18. Targeted Drug Delivery Systems and Biotechnological Products 505**
- Biotechnology 506
 - Drug Carriers and Targeting 514
 - Targeted Drug Delivery 519
 - Pharmacokinetics of Biopharmaceuticals 521
 - Bioequivalence and Comparability of Biotechnology-Derived Drug Products 522
 - Chapter Summary 523
 - Learning Questions 524
 - References 524
 - Bibliography 525
- 19. Relationship Between Pharmacokinetics and Pharmacodynamics 527**
- Pharmacodynamics and Pharmacokinetics 527
 - Relationship of Dose to Pharmacologic Effect 534
 - Relationship Between Dose and Duration of Activity (t_{eff}), Single IV Bolus Injection 536
 - Practice Problem 536
 - Effect of Both Dose and Elimination Half-Life on the Duration of Activity 537
 - Effect of Elimination Half-Life on Duration of Activity 537
 - Clinical Examples 539
 - Rate of Drug Absorption and Pharmacodynamic Response 541
 - Drug Tolerance and Physical Dependency 542
 - Hypersensitivity and Adverse Response 543

- 15. Drug Product Performance, *In Vivo*: Bioavailability and Bioequivalence 403**
- Drug Product Performance 403
 - Purpose of Bioavailability Studies 405
 - Relative and Absolute Availability 406
 - Practice Problem 407
 - Methods for Assessing Bioavailability 407
 - Bioequivalence Studies 413
 - Design and Evaluation of Bioequivalence Studies 414
 - Study Designs 417
 - Crossover Study Designs 418
 - Clinical Example 422
 - Evaluation of the Data 423
 - Bioequivalence Example 424
 - Study Submission and Drug Review Process 427
 - The Biopharmaceutics Classification System 431
 - Generic Biologics (Biosimilar Drug Products) 433
 - Clinical Significance of Bioequivalence Studies 435
 - Special Concerns in Bioavailability and Bioequivalence Studies 436
 - Generic Substitution 437
 - Glossary 440
 - Chapter Summary 443
 - Learning Questions 443
 - References 448
 - Bibliography 449
- 16. Impact of Drug Product Quality and Biopharmaceutics on Clinical Efficacy 451**
- Risks From Medicines 451
 - Drug Product Quality and Drug Product Performance 452
 - Pharmaceutical Development 453
 - Excipient Affect on Drug Product Performance 455
 - Practical Focus 456
 - Quality Control and Quality Assurance 457
 - Risk Management 459
 - Scale-Up and Postapproval Changes (SUPAC) 461
 - Product Quality Problems 464
 - Postmarketing Surveillance 465
 - Glossary 465
 - Chapter Summary 466
 - Learning Questions 466
 - References 466
- 17. Modified-Release Drug Products 469**
- Conventional (Immediate-Release) and Modified-Release Drug Products 469
 - Biopharmaceutic Factors 473
 - Dosage form Selection 475
 - Advantages and Disadvantages of Extended-Release Products 475
 - Kinetics of Extended-Release Dosage Forms 476
 - Pharmacokinetic Simulation of Extended-Release Products 478
 - Clinical Examples 480
 - Types of Extended-Release Products 480
 - Considerations in the Evaluation of Modified-Release Products 495
 - Evaluation of Modified-Release Products 497
 - Evaluation of *In Vivo* Bioavailability Data 499
 - Chapter Summary 501
 - Learning Questions 501
 - References 502
 - Bibliography 503
- 18. Targeted Drug Delivery Systems and Biotechnological Products 505**
- Biotechnology 506
 - Drug Carriers and Targeting 514
 - Targeted Drug Delivery 519
 - Pharmacokinetics of Biopharmaceuticals 521
 - Bioequivalence and Comparability of Biotechnology-Derived Drug Products 522
 - Chapter Summary 523
 - Learning Questions 524
 - References 524
 - Bibliography 525
- 19. Relationship Between Pharmacokinetics and Pharmacodynamics 527**
- Pharmacodynamics and Pharmacokinetics 527
 - Relationship of Dose to Pharmacologic Effect 534
 - Relationship Between Dose and Duration of Activity (t_{eff}), Single IV Bolus Injection 536
 - Practice Problem 536
 - Effect of Both Dose and Elimination Half-Life on the Duration of Activity 537
 - Effect of Elimination Half-Life on Duration of Activity 537
 - Clinical Examples 539
 - Rate of Drug Absorption and Pharmacodynamic Response 541
 - Drug Tolerance and Physical Dependency 542
 - Hypersensitivity and Adverse Response 543

- 15. Drug Product Performance, *In Vivo*: Bioavailability and Bioequivalence 403**
- Drug Product Performance 403
 - Purpose of Bioavailability Studies 405
 - Relative and Absolute Availability 406
 - Practice Problem 407
 - Methods for Assessing Bioavailability 407
 - Bioequivalence Studies 413
 - Design and Evaluation of Bioequivalence Studies 414
 - Study Designs 417
 - Crossover Study Designs 418
 - Clinical Example 422
 - Evaluation of the Data 423
 - Bioequivalence Example 424
 - Study Submission and Drug Review Process 427
 - The Biopharmaceutics Classification System 431
 - Generic Biologics (Biosimilar Drug Products) 433
 - Clinical Significance of Bioequivalence Studies 435
 - Special Concerns in Bioavailability and Bioequivalence Studies 436
 - Generic Substitution 437
 - Glossary 440
 - Chapter Summary 443
 - Learning Questions 443
 - References 448
 - Bibliography 449
- 16. Impact of Drug Product Quality and Biopharmaceutics on Clinical Efficacy 451**
- Risks From Medicines 451
 - Drug Product Quality and Drug Product Performance 452
 - Pharmaceutical Development 453
 - Excipient Affect on Drug Product Performance 455
 - Practical Focus 456
 - Quality Control and Quality Assurance 457
 - Risk Management 459
 - Scale-Up and Postapproval Changes (SUPAC) 461
 - Product Quality Problems 464
 - Postmarketing Surveillance 465
 - Glossary 465
 - Chapter Summary 466
 - Learning Questions 466
 - References 466
- 17. Modified-Release Drug Products 469**
- Conventional (Immediate-Release) and Modified-Release Drug Products 469
 - Biopharmaceutic Factors 473
 - Dosage form Selection 475
 - Advantages and Disadvantages of Extended-Release Products 475
 - Kinetics of Extended-Release Dosage Forms 476
 - Pharmacokinetic Simulation of Extended-Release Products 478
 - Clinical Examples 480
 - Types of Extended-Release Products 480
 - Considerations in the Evaluation of Modified-Release Products 495
 - Evaluation of Modified-Release Products 497
 - Evaluation of *In Vivo* Bioavailability Data 499
 - Chapter Summary 501
 - Learning Questions 501
 - References 502
 - Bibliography 503
- 18. Targeted Drug Delivery Systems and Biotechnological Products 505**
- Biotechnology 506
 - Drug Carriers and Targeting 514
 - Targeted Drug Delivery 519
 - Pharmacokinetics of Biopharmaceuticals 521
 - Bioequivalence and Comparability of Biotechnology-Derived Drug Products 522
 - Chapter Summary 523
 - Learning Questions 524
 - References 524
 - Bibliography 525
- 19. Relationship Between Pharmacokinetics and Pharmacodynamics 527**
- Pharmacodynamics and Pharmacokinetics 527
 - Relationship of Dose to Pharmacologic Effect 534
 - Relationship Between Dose and Duration of Activity (t_{eff}), Single IV Bolus Injection 536
 - Practice Problem 536
 - Effect of Both Dose and Elimination Half-Life on the Duration of Activity 537
 - Effect of Elimination Half-Life on Duration of Activity 537
 - Clinical Examples 539
 - Rate of Drug Absorption and Pharmacodynamic Response 541
 - Drug Tolerance and Physical Dependency 542
 - Hypersensitivity and Adverse Response 543

Drug Distribution and Pharmacologic Response	544
Pharmacodynamic Models	545
Drug Exposure-Pharmacologic Response Relationships	558
Chapter Summary	559
Learning Questions	560
References	561
Bibliography	563

20. Application of Pharmacokinetics to Clinical Situations 565

Medication Therapy Management	565
Individualization of Drug Dosage Regimens	566
Therapeutic Drug Monitoring	567
Clinical Example	574
Design of Dosage Regimens	576
Conversion from Intravenous Infusion to Oral Dosing	578
Determination of Dose	579
Practice Problems	580
Effect of Changing Dose and Dosing Interval on C_{\max}^{∞} , C_{\min}^{∞} , and C_{av}^{∞}	580
Determination of Frequency of Drug Administration	581
Determination of Both Dose and Dosage Interval	582
Determination of Route of Administration	583
Dosing of Drugs in Infants and Children	584
Dosing of Drugs in the Elderly	585
Dosing of Drugs in the Obese Patient	588
Pharmacokinetics of Drug Interactions	590
Inhibition of Drug Metabolism	594
Inhibition of Monoamine Oxidase (MAO)	595
Induction of Drug Metabolism	596
Inhibition of Drug Absorption	596
Inhibition of Biliary Excretion	596
Altered Renal Reabsorption Due to Changing Urinary pH	596
Practical Focus	597
Effect of Food on Drug Disposition	597
Adverse Drug Interactions	597
Population Pharmacokinetics	597
Regional Pharmacokinetics	608
Chapter Summary	609
Learning Questions	610
References	613
Bibliography	614

21. Dose Adjustment in Renal and Hepatic Disease 617

Renal Impairment	617
Pharmacokinetic Considerations	617

General Approaches for Dose Adjustment in Renal Disease	618
Measurement of Glomerular Filtration Rate	621
Serum Creatinine Concentration and Creatinine Clearance	622
Practice Problems	624
Dose Adjustment for Uremic Patients	627
Extracorporeal Removal of Drugs	638
Clinical Examples	642
Effect of Hepatic Disease on Pharmacokinetics	645
Chapter Summary	651
Learning Questions	652
References	653
Bibliography	655

22. Physiologic Pharmacokinetic Models, Mean Residence Time, and Statistical Moment Theory 657

Physiologic Pharmacokinetic Models	658
Mean Residence Time	670
Statistical Moment Theory	674
Selection of Pharmacokinetic Models	687
Chapter Summary	689
Learning Questions	689
References	690
Bibliography	691

Appendix A Statistics 693

Appendix B Applications of Computers in Pharmacokinetics 707

Appendix C Solutions to Frequently Asked Questions (FAQs) and Learning Questions 717

Appendix D Guiding Principles for Human and Animal Research 761

Appendix E Popular Drugs and Pharmacokinetic Parameters 767

Index	773
-------	-----